Clinical Trials Browser

Phase 2 × Pemetrexed × Genitourinary × Clear all

NCT05335941 2026-03-04

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

Phase 2 Active not recruiting

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT06630416 2026-02-24

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Phase 2 Recruiting

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT02693717 2021-05-20

Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer

Phase 2 Terminated

7 enrolled 5 charts

Carcinoma, Transitional Cell

NCT01490437 2014-09-25

PECULIAR

Phase 2 Completed

Carcinoma, Transitional Cell

NCT00491075 2013-04-24

Pemetrexed Plus Gemcitabine in Renal Cell Cancer

Phase 2 Terminated

16 enrolled 7 charts

Carcinoma, Renal Cell

NCT00034593 2006-07-19

A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Phase 2 Completed

Urinary Bladder Neoplasms, Neoplasm Metastasis, Urologic Neoplasms

NCT00035061 2006-07-19

A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

Phase 2 Completed

Urinary Bladder Neoplasms, Neoplasm Metastasis, Recurrence, Urologic Neoplasms